VIVUS Target of Unusually High Options Trading (VVUS)
VIVUS (NASDAQ:VVUS) was the recipient of some unusual options trading activity on Monday. Stock traders purchased 7,795 put options on the stock, Analyst Ratings.Net reports. This represents an increase of 322% compared to the average daily volume of 1,846 put options.
A number of research firms have recently commented on VVUS. Analysts at Leerink Swann reiterated an “outperform” rating on shares of VIVUS in a research note to investors on Friday. They now have a $20.00 price target on the stock. Finally, analysts at Cowen and Company upgraded shares of VIVUS from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, October 3rd. They now have a $19.00 price target on the stock, up previously from $13.50. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.09.
VIVUS (NASDAQ:VVUS) traded down 6.17% on Monday, hitting $10.50. The stock had a trading volume of 3,531,742 shares. VIVUS has a 52 week low of $9.11 and a 52 week high of $23.59. The stock’s 50-day moving average is $10.76 and its 200-day moving average is $12.51. The company’s market cap is $1.059 billion.
VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.44) by $0.11. The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $12.76 million. During the same quarter in the prior year, the company posted ($0.24) earnings per share. On average, analysts predict that VIVUS will post $-1.97 earnings per share for the current fiscal year.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.